Arcus Biosciences, Inc. Files Definitive Proxy Statement
Ticker: RCUS · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1724521
Sentiment: neutral
Topics: DEF 14A, Proxy Statement, Executive Compensation, Equity Awards, Arcus Biosciences
TL;DR
<b>Arcus Biosciences, Inc. has filed its Definitive Proxy Statement detailing executive compensation and equity awards for the fiscal years 2020-2023.</b>
AI Summary
Arcus Biosciences, Inc. (RCUS) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Arcus Biosciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 23, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 3928 Point Eden Way, Hayward, CA 94545. The filing includes information related to equity awards granted to principal executive officers (PEO) and non-PEO/non-executive officers for the years 2020-2023. Details on the change in fair value of outstanding and unvested equity awards are provided for the same period.
Why It Matters
For investors and stakeholders tracking Arcus Biosciences, Inc., this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation, including equity awards, which is essential for informed voting decisions at the upcoming shareholder meeting. The detailed breakdown of equity awards and their fair values allows investors to assess the alignment of executive incentives with company performance and shareholder interests.
Risk Assessment
Risk Level: low — Arcus Biosciences, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosure on executive compensation and equity awards, with no immediate red flags or significant new information that would alter the risk profile.
Analyst Insight
Review the executive compensation details and equity award structures to understand potential impacts on shareholder value and executive incentives.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period for the DEF 14A)
- 2024-04-23 — Filing Date (Date the DEF 14A was filed)
- 2020-2023 — Equity Award Years (Period covered by equity award disclosures)
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Filer of the DEF 14A
- 3928 Point Eden Way, Hayward, CA 94545 (location) — Business and mailing address
FAQ
When did Arcus Biosciences, Inc. file this DEF 14A?
Arcus Biosciences, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Arcus Biosciences, Inc. (RCUS).
Where can I read the original DEF 14A filing from Arcus Biosciences, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Arcus Biosciences, Inc..
What are the key takeaways from Arcus Biosciences, Inc.'s DEF 14A?
Arcus Biosciences, Inc. filed this DEF 14A on April 23, 2024. Key takeaways: Arcus Biosciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 23, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 3928 Point Eden Way, Hayward, CA 94545..
Is Arcus Biosciences, Inc. a risky investment based on this filing?
Based on this DEF 14A, Arcus Biosciences, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosure on executive compensation and equity awards, with no immediate red flags or significant new information that would alter the risk profile.
What should investors do after reading Arcus Biosciences, Inc.'s DEF 14A?
Review the executive compensation details and equity award structures to understand potential impacts on shareholder value and executive incentives. The overall sentiment from this filing is neutral.
How does Arcus Biosciences, Inc. compare to its industry peers?
Arcus Biosciences operates in the pharmaceutical preparations industry, focusing on the development of novel cancer therapies.
Are there regulatory concerns for Arcus Biosciences, Inc.?
The filing is a standard SEC disclosure (DEF 14A) required for public companies regarding executive compensation and shareholder matters.
Industry Context
Arcus Biosciences operates in the pharmaceutical preparations industry, focusing on the development of novel cancer therapies.
Regulatory Implications
The filing is a standard SEC disclosure (DEF 14A) required for public companies regarding executive compensation and shareholder matters.
What Investors Should Do
- Analyze the equity award grants and vesting schedules for key executives.
- Evaluate the reported fair values of equity awards and their changes over the past four fiscal years.
- Understand the structure of the compensation committee's decisions regarding equity compensation.
Key Dates
- 2024-04-23: Filing of DEF 14A — Provides details on executive compensation and equity awards for fiscal years 2020-2023.
Year-Over-Year Comparison
This filing is a DEF 14A, which is a routine disclosure. No prior filing data for comparison is available in the provided text.
Filing Stats: 4,886 words · 20 min read · ~16 pages · Grade level 11.7 · Accepted 2024-04-23 16:08:51
Filing Documents
- rcus-20240423.htm (DEF 14A) — 866KB
- rcus-20240423_g1.jpg (GRAPHIC) — 23KB
- rcus-20240423_g2.jpg (GRAPHIC) — 31KB
- rcus-20240423_g3.jpg (GRAPHIC) — 63KB
- rcus-20240423_g4.jpg (GRAPHIC) — 66KB
- rcus-20240423_g5.jpg (GRAPHIC) — 125KB
- rcus-20240423_g6.jpg (GRAPHIC) — 102KB
- 0001724521-24-000079.txt ( ) — 2454KB
- rcus-20240423.xsd (EX-101.SCH) — 3KB
- rcus-20240423_def.xml (EX-101.DEF) — 2KB
- rcus-20240423_lab.xml (EX-101.LAB) — 3KB
- rcus-20240423_pre.xml (EX-101.PRE) — 1KB
- rcus-20240423_htm.xml (XML) — 123KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 21 EXECUTIVE OFFICERS 23
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 25 Compensation Discussion and Analysis 25 Summary Compensation Table 30 2023 Grants of Plan-Based Awards 31 Outstanding Equity Awa rds at 2023 F is cal Year End 31 2023 Option Exercises and Stock Vested 33 Severance and Change in Control Benefits 33 CEO Pay Ratio 35 Pay versus Performance 36 Compensation Committee Interlocks and Insider Participation 38 COMPENSATION OF DIRECTORS 39 EQUITY COMPENSATION PLAN INFORMATION 41 RELATED PERSON TRANSACTIONS 42 Policies and Procedures for Related Party Transactions 42 Certain Related-Person Transactions 42 HOUSEHOLDING OF PROXY MATERIALS 44 OTHER MATTERS 45 i QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the Board of Directors (the "Board") of Arcus Biosciences, Inc. ("Arcus") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the "Annual Meeting"), including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. What is included in the proxy materials? The proxy materials include: this proxy statement, which includes information regarding the proposals to be voted on at the Annual Meeting, the voting process, corporate governance, the compensation of our directors and certain executive officers, and other required information; our Annual Report on Form 10-K for the year